Diabetes in Old Age THIRD EDITION

Total Page:16

File Type:pdf, Size:1020Kb

Diabetes in Old Age THIRD EDITION Diabetes in Old Age THIRD EDITION Diabetes in Old Age Third Edition Edited by Alan J. Sinclair © 2009 John Wiley & Sons Ltd. ISBN: 978-0-470-06562-4 Other titles in the Wiley Diabetes in Practice Series Exercise and Sport in Diabetes Second Edition Edited by Dinesh Nagi 978 0470 022061 Complementary Therapies and the Management of Diabetes and Vascular Disease Edited by Patricia Dunning 978 0470 014585 Diabetes in Clinical Practice: Questions and Answers from Case Studies Edited by N. Katsilambros, E. Diakoumopoulou, I. Ioannidis, S. Liatis, K. Makrilakis, N. Tentolouris and P. Tsapogas 978 0470 035221 Obesity and Diabetes Second Edition Edited by Anthony Barnett and Sudhesh Kumar 9780 0470 848982 Prevention of Type 2 Diabetes Edited by Manfred Ganz 978 0470 857335 Diabetes – Chronic Complications Second Edition Edited by Kenneth Shaw and Michael Cummings 978 0470 865798 The Metabolic Syndrome Edited by Christopher Byrne and Sarah Wild 978 0470 025116 Psychology in Diabetes Care Second Edition Edited by Frank J. Snoek and T. Chas Skinner 978 0470 015049 The Foot in Diabetes Fourth Edition Edited by Andrew J. M. Boulton, Peter R. Cavanagh and Gerry Rayman 978 0470 015049 Gastrointestinal Function in Diabetes Mellitus Edited by Michael Horowitz and Melvin Samson 978 0471 899167 Diabetic Nephropathy Edited by Christopher Hasslacher 978 0471 589924 Nutritional Management of Diabetis Mellitus Edited by Gary Frost, Anne Dornhorst and David R. Hadden 978 0471 962045 Hypoglycaemia in Clinical Diabetes Second Edition Edited by Brian M. Frier and Miles Fisher 978 0470 018446 Diabetic Cardiology Edited by Miles Fisher and John McMurray 978 0470 862049 Diabetes in Old Age THIRD EDITION Editor Alan J. Sinclair Bedfordshire & Hertfordshire Postgraduate Medical School, University of Bedfordshire, UK A John Wiley & Sons, Ltd., Publication This edition first published 2009 © 2009 John Wiley & Sons Ltd. Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Other Editorial Offices 9600 Garsington Road, Oxford, OX4 2DQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom. ISBN: 978-0-470-06562-4 A catalogue record for this book is available from the British Library. Typeset in 9.75/11.75 Times Roman by Laserwords Private Limited, Chennai, India Printed and bound in Great Britain by Antony Rowe Ltd, Chippenham, Wilts First Impression 2009 Contents Foreword xi 3.3 Why detect diabetes? 23 3.4 The symptoms of diabetes 24 Preface xv 3.5 Glycosuria 25 3.6 Fasting plasma glucose and the modified oral List of Contributors xvii glucose tolerance test 25 3.7 Random and postprandial plasma glucose 27 3.8 Blood glucose meters 28 SECTION I EPIDEMIOLOGY AND 3.9 Glycosylated haemoglobin 29 PATHOPHYSIOLOGY 3.10 Fructosamine 30 3.11 Diabetes prediction calculators 31 3.12 Known diabetes 31 1 Pathophysiology of Diabetes In The Elderly 3 3.13 Types of diabetes 32 Graydon S. Meneilly 3.14 Metabolic syndrome 33 1.1 Introduction 3 3.15 Future research 33 1.2 Diet and diabetes in the elderly 4 3.16 Conclusions 33 1.3 Other factors 5 References 34 1.4 Metabolic alterations 5 1.5 Molecular biology studies 8 1.6 Glucose counter-regulation 8 SECTION III VASCULAR COMPLICATIONS 1.7 Conclusions 9 Acknowledgments 9 4 Peripheral Arterial Disease in Old People with References 9 Diabetes 41 2 Diabetes-Related Risk Factors In Leocadio Rodrıguez´ Ma˜nas, Cristina Alonso Older People 13 Bouzon and Marta Castro Rodrıguez´ Stephen Colagiuri and Daniel Davies 4.1 Introduction 41 2.1 Introduction 13 4.2 Epidemiology of peripheral arterial disease 42 2.2 Age 13 4.3 Pathophysiology 42 2.3 Impaired glucose tolerance (IGT) and impaired 4.4 Clinical presentation 45 fasting glucose (IFG) 14 4.5 Diagnostic methods 46 2.4 Body weight 14 4.6 Treatment 47 2.5 Ethnicity 14 References 48 2.6 Gestational diabetes mellitus (GDM) 14 2.7 Family history 14 5 Coronary Heart Disease 51 2.8 Hypertension 15 2.9 Cardiovascular and cerebrovascular disease 15 Ahmed H. Abdelhafiz 2.10 Physical inactivity 15 5.1 Introduction 51 2.11 Antipsychotic medication and Mental Illness 15 5.2 Effect of ageing and diabetes on the 2.12 Sleep disorders 16 cardiovascular system 51 2.13 Smoking 16 5.3 Epidemiology 53 2.14 Conclusions 16 5.4 Cardiovascular risks 53 References 16 5.5 Myocardial infarction 61 5.6 Heart failure 63 5.7 Anti-diabetic medications and CHD 64 SECTION II SCREENING AND 5.8 Conclusions 66 DIAGNOSIS References 66 3 Diabetes in the Elderly: Diagnosis, Testing 6 Stroke and Diabetes 75 and Screening 21 Janice E. O’Connell and Christopher S. Gray Simon Croxson 6.1 Introduction 75 3.1 Introduction 21 6.2 Diabetes, hyperglycaemia and stroke risk in older 3.2 Definition of diabetes in the elderly 21 people 76 vi CONTENTS 6.3 Diabetes, post-stroke hyperglycaemia and 10.9 Pressure palsies 141 prognosis after acute stroke 79 10.10 Pathogenesis of diabetic peripheral neuropathy 142 6.4 Diabetes, hyperglycaemia and acute stroke 10.11 Autonomic neuropathy 142 treatment 80 10.12 Management of painful diabetic neuropathy 144 6.5 Stroke prevention in type 2 diabetes 84 References 146 6.6 Conclusions 87 References 88 11 Erectile Dysfunction 149 Tam´as V´arkonyi and Peter Kempler 7 Diabetes-Related Renal Disease in Older 11.1 Introduction 149 People 93 11.2 Erectile dysfunction: An observable marker of Latana A. Munang and John M. Starr diabetes mellitus? 150 7.1 Introduction 93 11.3 Risk factors of erectile dysfunction 150 7.2 Changes in the diabetic kidney 93 11.4 Pathophysiology of ED in diabetes mellitus 151 7.3 Screening for diabetic renal disease 94 11.5 Erectile dysfunction: A first sign of 7.4 Chronic kidney disease 95 cardiovascular disease? 151 7.5 Management of diabetic renal disease 95 11.6 The artery size hypothesis: A macrovascular 7.6 Managing cardiovascular risk 97 link between ED and CAD 152 7.7 Management of CKD and its complications 97 11.7 Other causes of erectile dysfunction 152 7.8 Conservative management of renal disease 98 11.8 Differentiation between organic and 7.9 Conclusions 99 psychogenic erectile dysfunction 153 References 100 11.9 Treatment of erectile dysfunction in diabetic patients 153 11.10 Conclusions 158 8 Management of Eye Disease and Visual Loss 103 References 158 Nina Tumosa 8.1 Introduction 103 8.2 Risk factors 103 SECTION IV TREATMENT AND CARE ISSUES 8.3 Management of diabetic retinopathy 104 8.4 Treatments of diabetic retinopathy 106 12 Metabolic Risk Factors, Obesity and 8.5 Conclusions 109 Cardiometabolic Syndrome 165 References 110 Raffaele Marfella and Giuseppe Paolisso 9 The Diabetic Foot 113 12.1 The definition of metabolic syndrome 165 12.2 Pathogenesis of the metabolic syndrome 167 Andrew J.
Recommended publications
  • SAL Farooqiq7 PD 3-Col
    State of the art lecture Primary care: the custodian of diabetes care? Azhar Farooqi Abstract General Practitioner and Honorary Professor, Type 2 diabetes is the disease of our times. With some 3 million cases in the UK, primary care University of Leicester, East Leicester Medical Practice, has a vital role in coordinating and delivering evidence-based care which includes the Leicester, UK prevention, detection and management of diabetes. However, primary care has not always been able to deliver such a role; up to the end of the 1980s, despite the drawbacks of busy hospital outpatient clinics, primary care could rarely Correspondence to: offer the systematic care and skills that people with diabetes require. Professor Azhar Farooqi OBE, East Leicester Medical Quality improvement and audit in the 1990s heralded the increased adoption of Practice, 131 Uppingham Rd, Leicester LE5 4BP, UK; email: [email protected] evidence-based practice in primary care. Many GP practices significantly improved the organisation and quality of care for diabetes as a result. The widespread adoption of IT Received: 30 July 2012 systems and the emergence of a more robust evidence base for care (for example, UKPDS) Accepted: 1 August 2012 accelerated this process. More lately, investment in general practice through the Quality and Outcomes Framework This paper was presented as the 2012 Mary and practice education programmes have helped deliver significant improvements in the Mackinnon lecture at the 2012 Diabetes UK Annual quality of primary care diabetes. Professional Conference held in Glasgow However, there is still much to do, with variation in care and health inequalities persisting.
    [Show full text]
  • To View the Programme at a Glance
    Key BS Basic science Awards sessions Masterclasses Poster sessions Wednesday, 6 March 2019 CC Community care Breaks Named Lectures Sponsored symposia sessions CS Clinical science Diabetes UK professional Oral abstract sessions Symposia sessions PC Primary care interest groups Plenary sessions Workshops SC Specialist care From 7.45 Registration, exhibition and posters 8.45 –10.25 Hall 1 Opening plenary 8.45 Opening words Chris Askew, Diabetes UK Prevention and remission at scale: Paradigm shifts in Type 2 diabetes management (CC, CS, PC, SC) Chair: George Alberti, London 8.55 NHS Diabetes Prevention Programme update Jonathan Valabhji, London 9.10 Patient perspective Harry Matharu, High Wycombe 9.25 Diabetes remission: The DiRECT way Roy Taylor, Newcastle upon Tyne 9.40 Patient perspective David Paul, Warenford 9.55 Diabetes prevention: Can mass treatment be part of the strategy? Paul Aveyard, Oxford 10.10 Panel discussion 10.25 –11.05 Hall 1 Banting Memorial Lecture: The ongoing challenge of hypoglycaemia, a century after the discovery of insulin (CC, CS, PC, SC) Chair: Stephanie Amiel, London Simon Heller, Sheffield 11.05 –11.35 Coffee, exhibition, posters and Demonstration Theatre* 11.35 – Hall 1 Room 11 Hall 2L (Exhibition Hall) Room 3A Room 4 Arena (Exhibition Hall) Room 3B Room 12 12.35/13.05 11.35 –13.05 11.35 –13.05 11.35 –13.05 11.35 –12.35 11.35 –12.35 11.35 –13.05 11.35 –12.35 11.35 –12.35 Diabetic Medicine symposium: Psychological and emotional Enteral feeding with diabetes Reintegrating the Practical aspects of Audit Exercise
    [Show full text]
  • Research Project Directory Spring 2017
    Research Project Directory Spring 2017 Our research 2017-18 1 Introduction Welcome to our directory of research projects for 2017. I’m delighted to share with In 2016 we committed to supporting 35 new you the innovative research projects. I hope you enjoy reading about them we’re supporting across the and some of the other key bits of research we UK. Each project is only fund. By supporting us you’ll help us fund more possible thanks to the research in the future. continued support of our You can support research projects through our members, donors, fundraisers Adopt a Project scheme (page 6). You can also and local groups. find out more about each of the projects detailed We’ve been funding research for over 80 years, here at www.diabetes.org.uk/research awarding our first ever grant in 1935. Since then, we’ve seen some incredible steps forward in I’d like to once again thank all of our current diabetes care: the insulin pen, glucose meters, supporters – our work depends entirely on your islet transplants. We’ve supported the researchers donations. Your support is absolutely vital. behind all of these breakthroughs. Please get in touch with us at [email protected] if you have any Every year we spend around £7 million on questions, comments or suggestions about world-leading diabetes research. That makes us our research. the largest charitable funder of diabetes research in the UK. The pioneering work we fund today covers all forms of diabetes and related complications. Everything we know about managing and treating diabetes is thanks to Dr Elizabeth Robertson research.
    [Show full text]
  • 2018 Annual Report & Financial Statements(PDF
    Our story Annual report and accounts 2018 Contents Foreword 4 Our vision, mission and values 6 Our strategy 8 Our year in numbers 10 Strategic report: Knowledge is power 12 Getting together, giving support 16 Research changing lives 20 Raising standards in care 24 Preventing Type 2 diabetes 28 Making life easier 32 The fight for Flash 36 Making it happen: partnerships 40 Making it happen: volunteers 44 Making it happen: fundraisers 48 Thank you 54 Future plans 56 Get involved 58 Get support 60 Our finances and how we are run 62 Independent auditor’s report 85 Financial statements 2018 90 Foreword As we reflect on a year of huge achievement for people living with and Our own fundraising events like Swim22 and the One Million Step Challenge at risk of diabetes, a simple but important truth is powerfully clear: grew significantly in 2018, while the growth in our partnership and philanthropy together we achieve more. It’s an idea that shines through our story of fundraising has played an important part too. As always, we are indebted to 2018 time and again. every single person who has supported our work. Thank you. We’re proud to have worked alongside people with diabetes, healthcare While we reflect on our successes in 2018, we cannot shy away from how the professionals and NHS leaders, and to have joined forces with the business changing world around us affects the way we provide the support, information community and other charities. Our world-class researchers, life-changing and research that people need. At the time of writing, we continue to demand campaigners and fundraisers make it all possible and, vitally, our work that the government ensures the vital needs of people with diabetes are met continues to be inspired by people whose lives have been affected by when we leave the European Union.
    [Show full text]
  • Diabetes UK Annual Report and Accounts 2019
    our story Annual report and accounts 2019 Contents Foreword 4 Our vision, our values, our mission 6 Our strategy 8 Our year in numbers 10 Strategic report: Shining a light on mental health 12 The remission revolution 16 Life-changing advances in research 20 Reducing the risk of type 2 24 Support at every step 28 The best care for everyone 32 Partners in our vision 36 Thank you 40 Our future plans 46 Get involved 50 Get support 52 Our finances and how we’re run 54 Independent auditor’s report 78 Financial statements 2019 82 Contents Foreword Welcome to our Annual Report 2019, in which we are proud to share all that we achieved last year, and introduce you to a few of the people for whom our work made a difference. Thank you to everyone – each individual supporter, community group, philanthropic organisation and business – who has supported us to achieve so much for so many in the past 12 months. At the time of writing this introduction, we are in the midst of the coronavirus (Covid-19) pandemic. As a charity, we are meeting unprecedented levels of demand upon our services, by many thousands of people living with or near diabetes who are understandably concerned or worried or who are seeking guidance and support. At the same time as meeting the calls upon us, we are steering the charity through the impacts of loss of income and of severe disruption to our work, whilst ensuring that all our staff are supported to do their work and to look after their own health and that of their loved ones.
    [Show full text]
  • Wednesday, 14 March 2018
    Key BS Basic science Awards sessions Oral abstract sessions Sponsored symposia sessions Wednesday, 14 March 2018 CS Clinical science Diabetes UK professional Plenary sessions Symposia sessions PC Primary care interest groups Poster sessions Workshops SC Secondary care Named lectures Breaks From 7.45 Registration, exhibition and posters 8.45 –10.25 ICC Auditorium Opening plenary 8.45 Opening words Chris Askew, Diabetes UK Cardiovascular risk reduction in diabetes: Maximising patient benefits (CS, PC, SC) Chair: Naveed Sattar, Glasgow 8.55 Epidemiology: The burden of cardiovascular disease in people with diabetes – Martin Rutter, Manchester 9.13 New clinical trials: The promise of added benefit – David Preiss, Oxford 9.31 Making cardiovascular disease risk reduction happen in primary care – Tony Willis, London 9.49 A patients perspective on cardiovascular disease risk reduction in diabetes – David Garrell, Dundee 10.07 Open discussion 10.25 –10.55 ICC Auditorium Plenary session with Simon Stevens Chair: Chris Askew, Diabetes UK Simon Stevens, NHS England 10.55 –11.35 Coffee, exhibition and posters 11.35 – ICC Auditorium Rooms 8–11 Rooms 7 and 12 Rooms 3 and 4 Arena (Exhibition Hall) Room 14 Room 17 Rooms 15 and 16 12.35/13.05 11.35–13.05 11.35–13.05 11.35–12.35 11.35–12.35 11.35–12.35 11.35–13.05 11.35–13.05 11.35–12.35 Diabetes UK’s evidence based Inpatient care and the National The REPOSE trial Diabetes and cancer Weaving psychological Population health Workshop: Sponsored nutrition guidelines for the Diabetes Inpatient Audit (NaDIA) of insulin pump therapy (CS, SC) principles into routine (CS) Hypoglycaemia: symposia: prevention and management (CS, SC) vs.
    [Show full text]
  • PROJECT DIRECTORY 2016 –17 RESEARCH SPOTLIGHTS INTRODUCTION 03 Welcome to Diabetes UK’S 2016–2017 MIKE’S STORY Research Directory
    PROJECT DIRECTORY 2016 –17 RESEARCH SPOTLIGHTS INTRODUCTION 03 Welcome to Diabetes UK’s 2016–2017 MIKE’S STORY Research Directory. We’re delighted to 04 share with you the innovative studies we’re supporting across the UK. Each ADOPT A PROJECT 05 one is only possible thanks to the continued support of our members, 06 EASTERN donors and Diabetes UK groups. Everything we know about managing and treating diabetes LONDON is as a result of research. Diabetes UK awarded its first 07 research grant in 1935 and the impact of the research we’ve MIDLANDS funded over the last 85 years on people’s lives is immense. 15 For example, the first ever insulin pen, ‘Penject’, was released in 1983, designed by researchers in Glasgow and NORTH WEST 16 tested in a Diabetes UK trial involving 76 people with Type 1 diabetes. It replaced the traditional syringe and NORTHERN & YORKSHIRE influenced the pens that came after. Thanks to early 18 Diabetes UK funding, the insulin pen became an important NORTHERN IRELAND tool for people with Type 1 and Type 2 diabetes all over 21 the world. SCOTLAND We’re now the largest charitable funder of diabetes research 24 in the UK. The pioneering work we fund covers all forms of diabetes and related complications. Through research, we SOUTH EAST 28 can support the ideas and people that will transform the treatment and prevention of diabetes, and lead us to a cure. SOUTH WEST 32 Every year we spend around £7 million on new and ongoing diabetes research. In 2015 alone we committed to invest in WALES 33 new projects supporting established researchers and 25 leaders of the future.
    [Show full text]
  • Research Project Directory Spring 2018
    Research project directory Spring 2018 Our research 2018 1 Introduction Welcome to Diabetes UK’s directory of research projects for Spring 2018. I’m delighted to share with you the innovative research we’re supporting across the UK. Each project is only In 2017 alone, we supported 37 new projects possible thanks to the and committed around £7 million to world-leading continued support of our diabetes research. I hope that you enjoy reading members, donors and about the research we fund, and you might Diabetes UK groups. consider helping us fund more research in We’ve been funding the future. research for over 80 years, You can support research projects that interest awarding our first ever you through our Adopt a Project scheme (page 5). grant in 1935. Since then, To find out more about each project, go to we’ve seen some incredible steps forward in diabetes.org.uk/research. diabetes care: the insulin pen, glucose meters, I’d like to take this opportunity to personally thank islet transplants. The researchers behind these all of our current supporters. Without your donations, discoveries have all had our support. we wouldn’t be able to achieve what we do. We’re the largest charitable funder of diabetes Please get in touch with us at research in the UK. The pioneering work we fund [email protected] if you have any today covers all forms of diabetes and related questions, comments or suggestions about complications. Everything we know about our research. managing and treating diabetes is thanks to research. And through this, we want to reach a world where diabetes can do no harm.
    [Show full text]
  • Conference Program
    AASD 2020 16TH INTERNATIONAL CONFERENCE OF ARABIC ASSOCIATION FOR THE STUDY OF DIABETES AND METABOLISM الجمعية العربية لدراسة أمراض السكر والميتابوليزم MEMBER OF INTERNATIONAL DIABETES FEDERATION, IDF 28 – 31 OCTOBER, 2020, EGYPT VIRTUAL MEETING Guest of Honor Prof Andrew JM Boulton IDF President AASD & Conference Honorary President Prof Raafat Rashwan AASD & Conference President Prof Inass Shaltout AASD & Conference Vice-President Prof Amr Abdel Wahab Conference Vice-President Prof Mohamed Hassanein Conference is accredited with 20 hours By (CEMTA) 1 AASD 2020 Guest of Honor IDF President Prof Andrew JM Boulton AASD & Conference Honorary President Prof Raafat Rashwan AASD & Conference President Prof Inass Shaltout AASD & Conference Vice-President Prof Amr Abdel Wahab Conference Vice-President Prof Mohamed Hassanein 2 Conference & AASD Secretary Prof Omar El-Saadany Prof Abdel Khalek Hamed Prof Hazem El Ashmawy Scientific Committee Chairmen Prof Amr Elmeligi Prof Ashraf Attia Prof Atef Elbahry Prof Mohamed Naguieb Prof Shereen Abdel Ghaffar Prof Yasser Abdel Hamid Dr Nader Wadie Scientific Committee Moderators AASD Treasure Dr Mazen Attia Dr Hisham Habib Dr. Sayed Gad 3 16TH International Conference of Arabic Association for the Study of Diabetes and Metabolism (AASD) Member of International Diabetes Federation, IDF Dear professors and colleagues, It gives us a great pleasure to welcome you in 16th annual virtual AASD conference. On behalf of AASD board and members, we appreciate the strong participation and support of International Diabetes Federation, IDF. AASD as a member of IDF puts a great responsibility on all AASD members to do extra efforts for the cause of Diabetes. Let me express our gratitude to prof Andrew Boulton, president of the International Diabetes Federation and guest of honor of AASD conference 2020 for his extraordinary support of all AASD activities.
    [Show full text]